Department of Pharmacology, National Organization for Drug Control and Research (NODCAR), Giza, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Eur J Pharmacol. 2017 Jun 15;805:118-124. doi: 10.1016/j.ejphar.2017.02.046. Epub 2017 Feb 28.
Sildenafil and febuxostat protect against doxorubicin-induced nephrotoxicity; however the exact mechanism remains to be elucidated. The effect of sildenafil and febuxostat on doxorubicin-induced nephrotoxicity in rats was studied. Male rats were subdivided into nine groups. The 1st group served as normal control, the 2nd group received dimethylsulfoxide 50% (DMSO), the 3rd group received doxorubicin (3.5mg/kg, i.p.), twice weekly for 3 weeks. The next 3 groups received sildenafil (5mg/kg; p.o.), febuxostat (10mg/kg; p.o.) and their combination, respectively daily for 21 days. The last 3 groups received doxorubicin in combination with sildenafil, febuxostat or their combination. Nephrotoxicity was evaluated histopathologically by light microscopy and biochemically through measuring the following parameters, Kidney function biomarkers [serum levels of urea, creatinine and uric acid], oxidative stress biomarkers [kidney contents of glutathione reduced (GSH) and malondialdehyde (MDA)], The apoptotic marker namely; caspase-3 in kidney tissue and the inflammatory mediator tumor necrosis factor alpha (TNF-α). doxorubicin-induced a significant elevation in nephrotoxicity markers, expression of caspase-3 and caused induction of inflammation and oxidative stress. Histological changes in the kidney was tubular necrosis. Sildenafil and/or febuxostat administration with doxorubicin caused a significant decrease in nephrotoxicity markers and inflammatory mediators, restoration of normal values of oxidative stress biomarkers and hampering the expression of renal caspase-3. They also ameliorate histological changes induced by doxorubicin. sildenafil and febuxostat are promising protective agents against doxorubicin-nephrotoxicity through improving biochemical, inflammatory, histopathological and immunohistochemical alterations induced by doxorubicin.
西地那非和非布司他可预防阿霉素诱导的肾毒性;然而,其确切机制仍有待阐明。本研究旨在探讨西地那非和非布司他对阿霉素诱导的大鼠肾毒性的影响。雄性大鼠被分为 9 组。第 1 组作为正常对照组,第 2 组给予二甲基亚砜 50%(DMSO),第 3 组给予阿霉素(3.5mg/kg,腹腔注射),每周 2 次,共 3 周。接下来的 3 组分别给予西地那非(5mg/kg;口服)、非布司他(10mg/kg;口服)及其联合用药,每天 1 次,共 21 天。最后 3 组给予阿霉素联合西地那非、非布司他或二者联合用药。通过光镜观察和测定以下参数对肾毒性进行组织病理学和生化评估:肾功能生物标志物[血清尿素、肌酐和尿酸水平]、氧化应激生物标志物[肾脏还原型谷胱甘肽(GSH)和丙二醛(MDA)含量]、肾组织中的凋亡标志物[胱天蛋白酶-3]和炎症介质肿瘤坏死因子-α(TNF-α)。阿霉素诱导的肾毒性标志物显著升高,caspase-3 表达增加,并导致炎症和氧化应激的诱导。肾脏组织学变化为肾小管坏死。西地那非和/或非布司他与阿霉素联合给药可显著降低肾毒性标志物和炎症介质,恢复氧化应激生物标志物的正常水平,并抑制肾组织中 caspase-3 的表达。它们还可改善阿霉素诱导的组织学变化。西地那非和非布司他通过改善阿霉素诱导的生化、炎症、组织病理学和免疫组化改变,是阿霉素肾毒性的有前途的保护剂。